Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiplatelet strategy in elderly acute coronary syndrome patients after PCI
ChiCTR2200062478Phase 4Not yet recruiting
- Sponsor
- Fuwai Hospital
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor, clopidogrel and aspirin in acute coronary syndrome (ACS) (3 arms), sponsored by Fuwai Hospital. Primary endpoint: Adenosine diphosphate-induced platelet-fibrin clot strength (MAADP). Planned start Aug 2022; status: not yet recruiting.
02
Drugs
ticagrelorclopidogrelaspirin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2200062478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062478.